High-Sensitivity Troponin T and Copeptin in Non-ST Acute Coronary Syndromes: Implications for Prognosis and Role of hsTnT and Copeptin in Non-STEACS
Table 1
Baseline characteristics of patients and controls.
Non-STEACS
Disease controls
Healthy controls
122
33
43
Age (mean ± SD)
Male sex (%)
83 (68.0)
31 (93.9)
17 (39.5)
Hypertension (%)
92 (75.4)
26 (78.8)
23 (53.5)
Diabetes mellitus (%)
40 (32.8)
14 (42.4)
10 (23.3)
Hypercholesterolemia (%)
67 (54.9)
20 (60.6)
11 (25.6)
Smoking habit (%)
27 (22.1)
—
—
Medications
—
—
Aspirin (%)
120 (98.4)
—
—
Clopidogrel (%)
120 (98.4)
—
—
ARBs (%)
34 (27.9)
—
—
Beta-blocker (%)
50 (41.0)
—
—
ACE inhibitors (%)
33 (27)
—
—
CA (%)
25 (20.5)
—
—
Statins (%)
64 (52.0)
—
—
ST deviation (%)
39 (32)
—
—
TIMI risk score (mean ± SD)
—
—
Catheterism (%)
64 (52.5)
Stent carrier (%)
54 (43.9)
hsTnT (ng/mL)
0.010 (0.005–0.023)
0.008 (0.005–0.011)
0.004 (0.003–0.007)
Copeptin >14 pmol/mL (%)
10 (8.2)
4 (12.1)
1 (2.3)
Copeptin (pmol/L)
8.42 (5.60–13.35)
11.67 (7.08–14.56)
6.51 (4.80–9.08)
High-sensitivity troponin T (hsTnT) and copeptin levels data shown as median (IQR). NSTEACS: non ST-elevation acute coronary syndrome; ARBs: angiotensin receptor blockers; ACE: angiotensin-converting enzyme; CA: calcium antagonists.
